<!doctype html>
<html data-n-head-ssr>
  <head>
    <title>新闻中心</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width,initial-scale=1"><meta data-n-head="ssr" data-hid="description" name="description" content=""><link data-n-head="ssr" rel="icon" type="image/x-icon" href="/favicon.ico"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/runtime.740a1d4.js" as="script"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/commons.app.bea3805.js" as="script"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/vendors.app.2feb4b5.css" as="style"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/vendors.app.6f09bab.js" as="script"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/app.c4b7f37.css" as="style"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/app.d847260.js" as="script"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/pages/news.eb8a4f6.css" as="style"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/pages/news.be408d5.js" as="script"><link rel="stylesheet" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/vendors.app.2feb4b5.css"><link rel="stylesheet" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/app.c4b7f37.css"><link rel="stylesheet" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/pages/news.eb8a4f6.css"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/static/1607852339/news/payload.js" as="script"><link rel="preload" href="https://static.yladm.com/Transformers/yilan-web/1.0.1/static/1607852339/manifest.js" as="script">
  </head>
  <body>
    <div data-server-rendered="true" id="__nuxt"><!----><div id="__layout"><div><section id="components-layout-demo-top" class="layout ant-layout"><header class="ant-layout-header"><div class="logo"></div> <ul role="menu" class="ant-menu ant-menu-horizontal ant-menu-root ant-menu-light" style="line-height:64px"><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="display:none"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li><li role="menuitem" class="ant-menu-item"><a href="/" class="nuxt-link-active">首页</a></li><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="display:none"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li><li role="menuitem" class="ant-menu-item"><a href="/product">产品中心</a></li><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="display:none"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li><li role="menuitem" class="ant-menu-item ant-menu-item-selected"><a href="/news" aria-current="page" class="nuxt-link-exact-active nuxt-link-active">新闻中心</a></li><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="display:none"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li><li role="menuitem" class="ant-menu-item"><a href="/information">信息报告</a></li><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="display:none"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li><li role="menuitem" class="ant-menu-item"><a href="/about">关于我们</a></li><li role="menuitem" class="ant-menu-submenu ant-menu-submenu-horizontal ant-menu-overflowed-submenu" style="visibility:hidden;position:absolute"><div aria-haspopup="true" class="ant-menu-submenu-title"><span>···</span><i class="ant-menu-submenu-arrow"></i></div></li></ul></header> <main class="ant-layout-content mt"><div class="news-wrap" data-v-6acb902b><div class="gutter-wrap" data-v-1a17b2b1 data-v-6acb902b><div class="title" data-v-1a17b2b1>新闻中心</div> <div class="ant-row" style="margin-left:-8px;margin-right:-8px" data-v-1a17b2b1><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div><div class="gutter-row ant-col ant-col-8" style="padding-left:8px;padding-right:8px" data-v-1a17b2b1><div class="gutter-box" style="height:287px" data-v-1a17b2b1><div class="row-title" data-v-1a17b2b1>
          科济生物CT053全人抗BCMA CAR T细胞注射液纳入突破性治疗品种
        </div> <p class="desc" data-v-1a17b2b1>
          12月8日，科济生物宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗药物品种，拟定适应症为复发难治性多发性骨髓瘤(R/R MM)。宣布，其CT053全人抗BCMA自体CAR T细胞注射液通过CDE公示期，纳入突破性治疗
        </p> <p class="time" data-v-1a17b2b1>2020-12-09 15:12</p></div></div></div></div></div></main> <footer class="ant-layout-footer" style="text-align:center">
      北京一览科技有限公司 《互联网药品信息服务资格证书》的证书编号：XXXXXX
      联系我们：11102938
    </footer></section></div></div></div><script>window.__NUXT__={staticAssetsBase:"https://static.yladm.com/Transformers/yilan-web/1.0.1/static/1607852339",layout:"default",error:null,serverRendered:!0,routePath:"/news",config:{}}</script><script src="https://static.yladm.com/Transformers/yilan-web/1.0.1/runtime.740a1d4.js" defer></script><script src="https://static.yladm.com/Transformers/yilan-web/1.0.1/pages/news.be408d5.js" defer></script><script src="https://static.yladm.com/Transformers/yilan-web/1.0.1/commons.app.bea3805.js" defer></script><script src="https://static.yladm.com/Transformers/yilan-web/1.0.1/vendors.app.6f09bab.js" defer></script><script src="https://static.yladm.com/Transformers/yilan-web/1.0.1/app.d847260.js" defer></script>
  </body>
</html>
